Search results
Results from the WOW.Com Content Network
Kidney ischemia [1] is a disease with a high morbidity and mortality rate. [2] Blood vessels shrink and undergo apoptosis which results in poor blood flow in the kidneys. More complications happen when failure of the kidney functions result in toxicity in various parts of the body which may cause septic shock, hypovolemia, and a need for surgery. [3]
Acute kidney injury: Patients at risk for developing TLS (e.g. patients about to receive chemotherapy for a cancer with a high cell turnover rate, especially lymphomas and leukemias) should receive appropriate intravenous hydration in order to improve blood flow to the kidneys, maximize urine output, and ultimately prevent precipitation of uric ...
The treatment of kidney damage may reverse or delay the progression of the disease. [44] Kidney damage is treated by prescribing drugs: Corticosteroids : the result is a decrease in proteinuria and the risk of infection as well as a resolution of the edema.
There are various forms, [2] and some drugs may affect kidney function in more than one way. Nephrotoxins are substances displaying nephrotoxicity. Nephrotoxicity should not be confused with some medications predominantly excreted by the kidneys needing their dose adjusted for the decreased kidney function (e.g., heparin, lithium).
There's a new heart emoji on the block (since 2022), and its light blue hue, according to Emojipedia, epitomizes "love, friendship, feelings of warmth, and the color blue." Cheerful, if not ...
Another two emoji meanings that are often confused: This one, “weary face,” and “tired face” (below). The main difference is in the shape of the eyes, but they convey two separate feelings.
Taken as a whole, if the disease is limited to the kidney, only 20–30% develop metastatic disease after nephrectomy. [110] More specific subsets show a five-year survival rate of around 90–95% for tumors less than 4 cm. For larger tumors confined to the kidney without venous invasion, survival is still relatively good at 80–85%.
Denial of care in chronic kidney disease treatment and management is a significant issue for minority populations. This can be due to healthcare provider prejudice, structural barriers, and health insurance coverage disparities. Healthcare provider biases can lead to under-treatment, misdiagnosis, or delayed diagnosis.